Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Go back to Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 88.70 +14.18 (19.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $74.52 | 52 Week High | $8.22 | |||
| Open | $85.46 | 52 Week Low | $3.07 | |||
| Day High | $95.49 | P/E | N/A | |||
| Day Low | $84.34 | EPS | $-1.30 | |||
| Volume | 7,013,978 | |||||
| (NASDAQ: MDGL) | Delayed: 537.65 -9.14 (1.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $546.79 | 52 Week High | $18.24 | |||
| Open | $546.78 | 52 Week Low | $6.60 | |||
| Day High | $552.73 | P/E | N/A | |||
| Day Low | $536.42 | EPS | $0.00 | |||
| Volume | 310,899 | |||||
